MedTrace Logo

Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation

NCT03801135 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-01-11

No results posted yet for this study

Summary

Plasma exchange procedures remove procoagulant and anticoagulant factors. Every procedure increases the risk of bleeding and repeated procedures increase the risk of bleeding mostly because lower fibrinogen levels. The aim of study is to define coagulation status of patient after plasmapheresis with different laboratory tests and to investigate the possibility of fibrinogen concentrate replacement for the correction of induced coagulation disorder.

Conditions

  • Humoral Rejection
  • Guillain-Barre Syndrome
  • Miller Fisher Syndrome
  • CIDP
  • Good Pasture Syndrome
  • Hyperviscosity Syndrome

Interventions

DRUG

Fibrinogen concentrate

Haemocomplettan will be infused after plasma exchange procedure

OTHER

Fresh Frozen Plasma

Fresh frozen plasma will be part of replacement fluid

Sponsors & Collaborators

  • University Medical Centre Ljubljana

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-03
Primary Completion
2019-09-01
Completion
2019-09-24

Countries

  • Slovenia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03801135 on ClinicalTrials.gov